AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31374046 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (or another antidepressant) for 4 weeks after initial treatment
Number of subjects: 40
Study 29390284 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMC 2%
Number of subjects: 149
Study 26285326 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercises designed to treat pneumonia considering myofascial disorders
Number of subjects: 134
Study 26285326 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic physical exercises
Number of subjects: 134
Study 22520627 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil solution
Number of subjects: 35
Study 22520627 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation
Number of subjects: 35
Study 21035822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive weight loss intervention
Number of subjects: 212
Study 19471158 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow Dilution (FD)
Number of subjects: 48
Study 19471158 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line Dialysance (DD)
Number of subjects: 48
Study 17355761 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 2
Study 17355761 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric banding
Number of subjects: 2
Study 17355761 — intervention group
Group type: COMPARATOR
Intervention: Non-obese adults
Number of subjects: 2
Study 15325927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40
Study 15325927 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 14574175 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 37
Study 9786311 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU and leucovorin
Number of subjects: 0
Study 9786311 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion of 5-FU
Number of subjects: 0
Study 9786311 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI)
Number of subjects: 0
Study 9786311 — intervention group
Group type: COMPARATOR
Intervention: HAI
Number of subjects: 0
Study 9786311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluoropyrimidine-based therapies
Number of subjects: 0
Study 8723583 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg daily) for 14 or 9 days perioperatively, commencing 10 and 5 days preoperatively, respectively.
Number of subjects: 208
Study 8723583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 2182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (50 mg tid)
Number of subjects: 70
Study 2182401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 95488 — intervention group
Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy
Number of subjects: 51
Study 95488 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control)
Number of subjects: 51
Study 95488 — intervention group
Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy with early response
Number of subjects: 51
Study 95488 — intervention group
Group type: EXPERIMENTAL
Intervention: No response to BACFON polychemotherapy
Number of subjects: 51
Study 95488 — intervention group
Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy with radiotherapy
Number of subjects: 51
Study 95488 — intervention group
Group type: EXPERIMENTAL
Intervention: BACFON polychemotherapy without radiotherapy
Number of subjects: 51
Study 31086540 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV in addition to medicines and oxygen therapy (Intervention Group-A)
Number of subjects: 88
Study 31086540 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary comprehensive respiratory rehabilitation in addition to NIPPV and medicines and oxygen therapy (Intervention Group-B)
Number of subjects: 88
Study 31086540 — intervention group
Group type: COMPARATOR
Intervention: Control group (medicines and oxygen therapy)
Number of subjects: 88
Study 28320800 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved target sample size
Number of subjects: 151
Study 28320800 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved more than 80% of target sample size
Number of subjects: 151
Study 28320800 — intervention group
Group type: EXPERIMENTAL
Intervention: Median recruitment rate
Number of subjects: 151
Study 28320800 — intervention group
Group type: EXPERIMENTAL
Intervention: Median retention rate
Number of subjects: 151
Study 25171902 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/d
Number of subjects: 1199
Study 25171902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 23265346 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg/day
Number of subjects: 532
Study 23265346 — intervention group
Group type: COMPARATOR
Intervention: No colchicine
Number of subjects: 532
Study 23265346 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg/day (on-treatment analysis)
Number of subjects: 532
Study 23265346 — intervention group
Group type: COMPARATOR
Intervention: No colchicine (on-treatment analysis)
Number of subjects: 532
Study 21358204 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (oxaliplatin + oral capecitabine)
Number of subjects: 282
Study 21358204 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-6
Number of subjects: 282
Study 17965035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 38
Study 17965035 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise
Number of subjects: 38
Study 16491766 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-through-point acupuncture
Number of subjects: 224
Study 16491766 — intervention group
Group type: COMPARATOR
Intervention: General needling method (Control)
Number of subjects: 224
Study 14585280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 0
Study 14585280 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 0
Study 14585280 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PB and demethylating agents
Number of subjects: 0
Study 14585280 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of a demethylating agent and HDAC inhibitors
Number of subjects: 0
Study 10670599 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nomogram for managing anticoagulation therapy (Group A, n = 10)
Number of subjects: 20
Study 10670599 — intervention group
Group type: COMPARATOR
Intervention: No nomogram for managing anticoagulation therapy (Group B, n = 10)
Number of subjects: 20
Study 7853577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 437
Study 7853577 — intervention group
Group type: COMPARATOR
Intervention: RIVM-BCG
Number of subjects: 437
Study 7853577 — intervention group
Group type: COMPARATOR
Intervention: Tice BCG
Number of subjects: 437
Study 2200995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime-axetil (250 mg bid)
Number of subjects: 157
Study 2200995 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (500 mg/125 mg bid)
Number of subjects: 157
Study 6268131 — intervention group
Group type: EXPERIMENTAL
Intervention: MK 421
Number of subjects: 12
Study 6268131 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine analogue
Number of subjects: 12
Study 6268131 — intervention group
Group type: EXPERIMENTAL
Intervention: MK 421 or its lysine analogue
Number of subjects: 12
Study 31150573 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (gemcitabine 1 g/m² on days 1 and 8, cisplatin 80 mg/m² on day 1, every 3 weeks for three cycles) plus concurrent chemoradiotherapy
Number of subjects: 480
Study 31150573 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (gemcitabine and cisplatin) plus concurrent chemoradiotherapy
Number of subjects: 480
Study 31150573 — intervention group
Group type: COMPARATOR
Intervention: Standard-therapy (chemoradiotherapy alone)
Number of subjects: 480
Study 27117700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×10^6 tolDC
Number of subjects: 10
Study 27117700 — intervention group
Group type: EXPERIMENTAL
Intervention: 3×10^6 tolDC
Number of subjects: 10
Study 27117700 — intervention group
Group type: EXPERIMENTAL
Intervention: 10×10^6 tolDC
Number of subjects: 10
Study 27117700 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation (Control)
Number of subjects: 10
Study 26513512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 75
Study 26513512 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 75
Study 26513512 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy and Exposure therapy
Number of subjects: 75
Study 23426348 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube
Number of subjects: 187
Study 23426348 — intervention group
Group type: COMPARATOR
Intervention: No T-tube
Number of subjects: 187
Study 21193439 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 5715
Study 19852121 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 U BoNTA
Number of subjects: 60
Study 19852121 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 U BoNTA
Number of subjects: 60
Study 19852121 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 U BoNTA
Number of subjects: 60
Study 19852121 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (32 U, 64 U, 96 U)
Number of subjects: 60
Study 17990450 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (Kangliu Zengxiao Decoction during chemotherapy and Feiyanning Decoction after chemotherapy)
Number of subjects: 116
Study 17990450 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 116
Study 17990450 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine
Number of subjects: 116
Study 14993134 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with stenting (PCI)
Number of subjects: 1205
Study 14993134 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1205
Study 11396282 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 24
Study 11396282 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic CVVH for 5 days starting within 24 h following trauma
Number of subjects: 24
Study 10093631 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 10
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour sodium excretion rates
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour magnesium/creatinine excretion ratio
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour sodium excretion rate
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium/potassium ratio
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phospholipid
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol level
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum phospholipid n-3 polyunsaturated fatty acid (PUFA) level
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA to saturated fatty acid (SFA) ratio
Number of subjects: 400
Study 7919085 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour taurine excretion rate
Number of subjects: 400
Study 3337653 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine hydrochloride
Number of subjects: 102
Study 3337653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenoxybenzamine)
Number of subjects: 102
Study 29705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrostimulation + standard medical treatment
Number of subjects: 39
Study 29705158 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenic exercises + standard medical treatment
Number of subjects: 39
Study 29705158 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (control group)
Number of subjects: 39
Study 27557918 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse: CPP-ACP
Number of subjects: 40
Study 27557918 — intervention group
Group type: COMPARATOR
Intervention: Placebo mousse
Number of subjects: 40
Study 26715482 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational tool supported by a telephone call
Number of subjects: 31
Study 26715482 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 31
Study 24363761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin plus prednisone
Number of subjects: 88
Study 24363761 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A plus prednisone
Number of subjects: 88
Study 21406602 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Number of subjects: 0
Study 21406602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 0
Study 21406602 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (induction-positive control)
Number of subjects: 0
Study 18292443 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscopy (GVL)
Number of subjects: 20
Study 18292443 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 20
Study 18292443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GVL and DL
Number of subjects: 20
Study 17149995 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone outreach
Number of subjects: 6756
Study 17149995 — intervention group
Group type: EXPERIMENTAL
Intervention: Live caller outreach
Number of subjects: 6756
Study 17149995 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6756
Study 12960601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic salivary gland scintigraphy in group A (SS)
Number of subjects: 50
Study 12960601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic salivary gland scintigraphy in group B (autoimmune disorders)
Number of subjects: 50
Study 12960601 — intervention group
Group type: COMPARATOR
Intervention: Dynamic salivary gland scintigraphy in group C (controls)
Number of subjects: 50
Study 11192143 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram oral solution (10 mg/5 mL), 60 mg dose
Number of subjects: 24
Study 11192143 — intervention group
Group type: COMPARATOR
Intervention: Citalopram tablet, 60 mg dose
Number of subjects: 24
Study 9490580 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 60
Study 9490580 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 60
Study 8238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 71
Study 8238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate
Number of subjects: 71
Study 2418295 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous amrinone (200-400-800 micrograms/kg/h)
Number of subjects: 16
Study 2418295 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous amrinone (800-1600-3200 micrograms/kg/h)
Number of subjects: 16
Study 31315873 — intervention group
Group type: EXPERIMENTAL
Intervention: A Bite of ACT (online transdiagnostic psychoeducational intervention)
Number of subjects: 0
Study 31315873 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 28321839 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity Project intervention
Number of subjects: 215
Study 28321839 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 215
Study 26673432 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser
Number of subjects: 20
Study 26673432 — intervention group
Group type: COMPARATOR
Intervention: 595-nm PDL
Number of subjects: 20
Study 25036539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 102
Study 25036539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestalt-based intervention
Number of subjects: 102
Study 25036539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 102
Study 22298163 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin during the procedure
Number of subjects: 200
Study 22298163 — intervention group
Group type: EXPERIMENTAL
Intervention: One venous line cannulation with heparin
Number of subjects: 200
Study 22298163 — intervention group
Group type: COMPARATOR
Intervention: Separate cannulation without heparin
Number of subjects: 200
Study 22298163 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of in situ thrombosis rates by gender
Number of subjects: 200
Study 22298163 — intervention group
Group type: EXPERIMENTAL
Intervention: One venous line cannulation
Number of subjects: 200
Study 20557887 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg)
Number of subjects: 35
Study 20557887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 35
Study 17367358 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score derived from Cox regression model
Number of subjects: 399
Study 15761020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF during chemotherapy (Group B)
Number of subjects: 722
Study 15761020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF after chemotherapy until day 28 or recovery (Group C)
Number of subjects: 722
Study 15761020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF during and after chemotherapy (Group D)
Number of subjects: 722
Study 15761020 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF (Group A)
Number of subjects: 722
Study 15761020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF during chemotherapy (Groups B + D)
Number of subjects: 722
Study 15761020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF after chemotherapy (Groups C + D)
Number of subjects: 722
Study 15761020 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF after chemotherapy
Number of subjects: 722
Study 11931679 — intervention group
Group type: EXPERIMENTAL
Intervention: Social phobia group
Number of subjects: 33
Study 11931679 — intervention group
Group type: COMPARATOR
Intervention: Non-anxious group
Number of subjects: 33
Study 9797551 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid irrigation
Number of subjects: 31
Study 9797551 — intervention group
Group type: COMPARATOR
Intervention: Saline solution alone (Control)
Number of subjects: 31
Study 7707405 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (24 Gy in eight fractions over 12 days)
Number of subjects: 300
Study 7707405 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (control group)
Number of subjects: 300
Study 2468933 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg b.i.d.
Number of subjects: 26
Study 2468933 — intervention group
Group type: COMPARATOR
Intervention: Quinidine 500 mg b.i.d.
Number of subjects: 26
Study 2468933 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg b.i.d. (after dose adjustment)
Number of subjects: 26
Study 2468933 — intervention group
Group type: COMPARATOR
Intervention: Quinidine 500 mg b.i.d. (before and after dose adjustment)
Number of subjects: 26
Study 31751994 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk odor (BMO) group
Number of subjects: 0
Study 31751994 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubator cover (IC) group
Number of subjects: 0
Study 31751994 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice group
Number of subjects: 0
Study 31751994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29377257 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study 29377257 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 15 mg twice daily
Number of subjects: 0
Study 29377257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28124822 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide/metformin
Number of subjects: 30
Study 28124822 — intervention group
Group type: COMPARATOR
Intervention: Placebo/metformin
Number of subjects: 30
Study 24226297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 193) received a pack with tailored information, training plans, behaviour change booklets, and a pedometer.
Number of subjects: 402
Study 24226297 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 209) received health promotion leaflets.
Number of subjects: 402
Study 24226297 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of the intervention (three or more components).
Number of subjects: 402
Study 24226297 — intervention group
Group type: COMPARATOR
Intervention: No use of any aspect of the intervention.
Number of subjects: 402
Study 23241063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cervical periradicular steroid injection (US-CPSI)
Number of subjects: 59
Study 21397530 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment (endovascular and/or surgical)
Number of subjects: 201
Study 21397530 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive treatment
Number of subjects: 201
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: mtLSU rRNA nested PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: ITS nested PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) samples tested by MSG PCR
Number of subjects: 145
Study 19035050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) samples tested by mtLSU rRNA nested PCR
Number of subjects: 145